Biopharma Scholar Rock Q2 net loss widens, no revenue
Overview
Scholar Rock reports Q2 net loss of $110 mln, no revenue recorded
Cash reserves expected to support operations into 2027
Result Drivers
COSTS INCREASE - R&D costs increase $20 mln was due to higher drug supply manufacturing costs, employee related expenses
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | -$110.03 mln | ||
Q2 Basic EPS | -$0.98 | ||
Q2 Income from Operations | -$112.11 mln | ||
Q2 Operating Expenses | $112.11 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Scholar Rock Holding Corp is $52.00, about 28.9% above its August 5 closing price of $36.98
Press Release:
